Cases & Deals

Exonhit (now Diaxonhit) acquires leading independent distributor of in-vitro diagnostics in French market, InGen BioSciences

Clients Exonhit S.A. (now Diaxonhit)

Jones Day advised Exonhit SA (now Diaxonhit), a French leader in the field of in-vitro diagnostic listed on the Alternext market of NYSE Euronext Paris, in connection with the €18 million (US$22.9 million) acquisition of InGen BioSciences, the leading independent distributor of in-vitro diagnostics in the French market.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.